Zacks Investment Research lowered shares of Indivior (OTCMKTS:INVVY) from a hold rating to a sell rating in a report issued on Wednesday morning.

According to Zacks, “Indivior PLC operates as a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication and co-occurring conditions, such as schizophrenia. The Company markets and promotes SUBOXONE (buprenorphine and naloxone) Sublingual Film, SUBOXONE (buprenorphine and naloxone) Sublingual Tablet, and SUBUTEX (buprenorphine) Sublingual Tablet, each buprenorphine-based treatment for opioid. Indivior PLC is based in United States. “

Separately, ValuEngine raised shares of Indivior from a hold rating to a buy rating in a research report on Wednesday, November 29th.

Shares of Indivior (OTCMKTS INVVY) opened at $27.70 on Wednesday. The company has a market cap of $3,956.79, a P/E ratio of 110.80, a PEG ratio of 2.77 and a beta of 1.13. Indivior has a 12-month low of $17.50 and a 12-month high of $28.50.

TRADEMARK VIOLATION NOTICE: “Indivior (INVVY) Stock Rating Lowered by Zacks Investment Research” was originally posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another site, it was illegally copied and republished in violation of United States & international copyright laws. The correct version of this article can be read at

About Indivior

Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence worldwide. The company’s product candidates focus on treating opioid use disorder, alcohol use disorder, overdose rescue, and CNS disorders/schizophrenia.

Get a free copy of the Zacks research report on Indivior (INVVY)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with's FREE daily email newsletter.